236 related articles for article (PubMed ID: 32412097)
21. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
[TBL] [Abstract][Full Text] [Related]
22. ECT Has Greater Efficacy Than Fluoxetine in Alleviating the Burden of Illness for Patients with Major Depressive Disorder: A Taiwanese Pooled Analysis.
Lin CH; Huang CJ; Chen CC
Int J Neuropsychopharmacol; 2018 Jan; 21(1):63-72. PubMed ID: 29228200
[TBL] [Abstract][Full Text] [Related]
23. Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine.
Goodwin GM; Boyer P; Emsley R; Rouillon F; de Bodinat C
Int Clin Psychopharmacol; 2013 Jan; 28(1):20-8. PubMed ID: 23151774
[TBL] [Abstract][Full Text] [Related]
24. Electroconvulsive therapy improves clinical manifestation with plasma BDNF levels unchanged in treatment-resistant depression patients.
Lin CH; Chen MC; Lee WK; Chen CC; Huang CH; Lane HY
Neuropsychobiology; 2013; 68(2):110-5. PubMed ID: 23881232
[TBL] [Abstract][Full Text] [Related]
25. Negative cognitive schema modification as mediator of symptom improvement after electroconvulsive therapy in major depressive disorder.
Scheepens DS; van Waarde JA; Ten Doesschate F; Westra M; Kroes MCW; Schene AH; Schoevers RA; Denys D; Ruhé HG; van Wingen GA
J Affect Disord; 2022 Aug; 310():156-161. PubMed ID: 35490877
[TBL] [Abstract][Full Text] [Related]
26. Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.
Kennedy SH; Heun R; Avedisova A; Ahokas A; Olivier V; Picarel-Blanchot F; de Bodinat C
J Affect Disord; 2018 Oct; 238():122-128. PubMed ID: 29879606
[TBL] [Abstract][Full Text] [Related]
27. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
[TBL] [Abstract][Full Text] [Related]
28. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months.
Kennedy SH; Avedisova A; Belaïdi C; Picarel-Blanchot F; de Bodinat C
Eur Neuropsychopharmacol; 2016 Feb; 26(2):378-389. PubMed ID: 26708320
[TBL] [Abstract][Full Text] [Related]
29. Early improvement in HAMD-17 and HAMD-6 scores predicts ultimate response and remission for depressed patients treated with fluoxetine or ECT.
Lin HS; Lin CH
J Affect Disord; 2019 Feb; 245():91-97. PubMed ID: 30368075
[TBL] [Abstract][Full Text] [Related]
30. Cognitive remediation following electroconvulsive therapy in patients with treatment resistant depression: randomized controlled trail of an intervention for relapse prevention - study protocol.
Van de Velde N; Kappen M; Koster EHW; Hoorelbeke K; Tandt H; Verslype P; Baeken C; De Raedt R; Lemmens G; Vanderhasselt MA
BMC Psychiatry; 2020 Sep; 20(1):453. PubMed ID: 32938410
[TBL] [Abstract][Full Text] [Related]
31. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.
Stein DJ; Ahokas A; Márquez MS; Höschl C; Oh KS; Jarema M; Avedisova AS; Albarran C; Olivier V
J Clin Psychiatry; 2014 Apr; 75(4):362-8. PubMed ID: 24569045
[TBL] [Abstract][Full Text] [Related]
32. Long-term naturalistic follow-up of patients with bipolar depression and mixed state treated with electroconvulsive therapy.
Medda P; Mauri M; Fratta S; Ciaponi B; Miniati M; Toni C; Dell'Osso L; Perugi G
J ECT; 2013 Sep; 29(3):179-88. PubMed ID: 23899721
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of electroconvulsive therapy in patients with "less treatment-resistant" depression by the Maudsley Staging Model.
Ma Y; Rosenheck R; Ye B; Fan N; He H
Brain Behav; 2020 Jul; 10(7):e01654. PubMed ID: 32406210
[TBL] [Abstract][Full Text] [Related]
34. Episodic Visual Learning/Memory and Attentional Flexibility in Patients With Major Depressive Disorder After Clinically Effective Electroconvulsive Therapy.
Kalogerakou S; Oulis P; Anyfandi E; Konstantakopoulos G; Papakosta VM; Kontis D; Theochari E; Angelopoulos E; Zervas IM; Mellon RC; Papageorgiou CC; Tsaltas E
J ECT; 2015 Dec; 31(4):246-52. PubMed ID: 25973768
[TBL] [Abstract][Full Text] [Related]
35. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report.
Husain MM; Rush AJ; Fink M; Knapp R; Petrides G; Rummans T; Biggs MM; O'Connor K; Rasmussen K; Litle M; Zhao W; Bernstein HJ; Smith G; Mueller M; McClintock SM; Bailine SH; Kellner CH
J Clin Psychiatry; 2004 Apr; 65(4):485-91. PubMed ID: 15119910
[TBL] [Abstract][Full Text] [Related]
36. Actigraphy in patients with treatment-resistant depression undergoing electroconvulsive therapy.
Winkler D; Pjrek E; Lanzenberger R; Baldinger P; Eitel D; Kasper S; Frey R
J Psychiatr Res; 2014 Oct; 57():96-100. PubMed ID: 24998016
[TBL] [Abstract][Full Text] [Related]
37. Ketamine Anesthesia, Efficacy of Electroconvulsive Therapy, and Cognitive Functions in Treatment-Resistant Depression.
Rybakowski JK; Bodnar A; Krzywotulski M; Chlopocka-Wozniak M; Michalak M; Rosada-Kurasinska J; Bartkowska-Sniatkowska A
J ECT; 2016 Sep; 32(3):164-8. PubMed ID: 27008330
[TBL] [Abstract][Full Text] [Related]
38. Factors Related to the Changes in Quality of Life for Patients With Depression After an Acute Course of Electroconvulsive Therapy.
Huang CJ; Huang YH; Lin CH
J ECT; 2017 Jun; 33(2):126-133. PubMed ID: 27668944
[TBL] [Abstract][Full Text] [Related]
39. Electroconvulsive therapy and age: Age-related clinical features and effectiveness in treatment resistant major depressive episode.
Socci C; Medda P; Toni C; Lattanzi L; Tripodi B; Vannucchi G; Perugi G
J Affect Disord; 2018 Feb; 227():627-632. PubMed ID: 29172056
[TBL] [Abstract][Full Text] [Related]
40. Prevention of relapse with maintenance electroconvulsive therapy in elderly patients with major depressive episode.
Rapinesi C; Kotzalidis GD; Serata D; Del Casale A; Scatena P; Mazzarini L; Caccia F; Brugnoli R; Carbonetti P; Fensore C; Girardi P
J ECT; 2013 Mar; 29(1):61-4. PubMed ID: 23011573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
